Critical Care

official impact factor 4.60

This article is part of the supplement: Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma

Highly Access Review

Optimizing the use of blood products in trauma care

John R Hess1* and Seppo Hiippala2

Author Affiliations

1 Professor of Pathology and Medicine, Departments of Pathology and Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA

2 Department of Anesthesiology and Critical Care, University of Helsinki, Helsinki, Finland

For all author emails, please log on.

Critical Care 2005, 9(Suppl 5):S10-S14 doi:10.1186/cc3780

Published: 7 October 2005

Abstract

Blood transfusion has been used to treat the injured since the US Civil War. Now, it saves the lives of tens of thousands of injured patients each year. However, not everyone who receives blood benefits, and some recipients are injured by the transfusion itself. Effective blood therapy in trauma management requires an integration of information from diverse sources, including data relating to trauma and blood use epidemiology, medical systems management, and clinical care. Issues of current clinical concern in highly developed trauma systems include how to manage massive transfusion events, how to limit blood use and so minimize exposure to transfusion risks, how to integrate new hemorrhage control modalities, and how to deal with blood shortages. Less developed trauma systems are primarily concerned with speeding transport to specialized facilities and assembling trauma center resources. This article reviews the factors that effect blood use in urgent trauma care.